AbbVie inks deal for Medincell`s long-acting injectable platform worth up to $1.9B
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
MedinCell’s Partner Teva Provides Guidance for UZEDY in 2024
Teva Announces Recruitment Completion of Phase 3 Clinical Study of Olanzapine
MedinCell Applauds Teva and Royalty Pharma Collaboration
US Biopharma Financial & IR Strategy Veteran Dr Grace Kim joins MedinCell
MONTPELLIER, France--(BUSINESS WIRE)--MedinCell today announces that its partner, Arthritis Innovation Corporation (AIC), who conducts and finances all development activities of F14 (MedinCell codename: mdc-CWM), has completed the patient enrollment in the first of two Phase 3 clinical studies of F14 in patients undergoing total knee replacement (TKR). F14 (mdc-CWM) is a sustained-release formulation of the non-steroidal anti-inflammatory drug (NSAID), celecoxib, administered into the intra-articular space at the end of TKR surgery.
MedinCell’s Partner Teva Announces Successful Launch of UZEDY™
MONTPELLIER, France--(BUSINESS WIRE)--An original presentation describing pharmacokinetic characteristics of an investigational long-acting subcutaneous formulation of olanzapine (mdc-TJK or TEV-44749) will be communicated by MedinCell’s partner Teva Pharmaceuticals at the 2023 Schizophrenia Investigational Research Society (SIRS) later this month.